David J Riley
Overview
Explore the profile of David J Riley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
1218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghiandoni G, Evertsson E, Riley D, Tyrchan C, Rathi P
Drug Discov Today
. 2024 Mar;
29(4):103945.
PMID: 38460568
Design-Make-Test-Analyse (DMTA) is the discovery cycle through which molecules are designed, synthesised, and assayed to produce data that in turn are analysed to inform the next iteration. The process is...
2.
Tashkin D, Roth M, Clements P, Furst D, Khanna D, Kleerup E, et al.
Lancet Respir Med
. 2016 Jul;
4(9):708-719.
PMID: 27469583
Background: 12 months of oral cyclophosphamide has been shown to alter the progression of scleroderma-related interstitial lung disease when compared with placebo. However, toxicity was a concern and without continued...
3.
Chang Y, Sabourin C, Lu S, Sasaki T, Svoboda K, Gordon M, et al.
J Biochem Mol Toxicol
. 2009 Jun;
23(3):172-84.
PMID: 19526566
Epithelial cell migration during wound healing is regulated in part by enzymatic processing of laminin-332 (formerly LN-5), a heterodimer formed from alpha, beta, and gamma polypeptide chains. Under static conditions,...
4.
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease
Tashkin D, Elashoff R, Clements P, Roth M, Furst D, Silver R, et al.
Am J Respir Crit Care Med
. 2007 Aug;
176(10):1026-34.
PMID: 17717203
Rationale: The Scleroderma Lung Study enrolled 158 patients with scleroderma-related interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide (CYC). Although treatment-related benefits in pulmonary function, skin scores, and...
5.
Khanna D, Yan X, Tashkin D, Furst D, Elashoff R, Roth M, et al.
Arthritis Rheum
. 2007 May;
56(5):1676-84.
PMID: 17469162
Objective: To assess the impact of cyclophosphamide (CYC) on the health-related quality of life (HRQOL) of patients with scleroderma after 12 months of treatment. Methods: One hundred fifty-eight subjects participated...
6.
Riley D, Costanzo E
Curr Opin Pulm Med
. 2006 Aug;
12(5):331-6.
PMID: 16926647
Purpose Of Review: Our goal is to update advances in the use of surgical lung biopsy in the idiopathic interstitial pneumonias. We discuss an approach for identifying patients with idiopathic...
7.
Tashkin D, Elashoff R, Clements P, Goldin J, Roth M, Furst D, et al.
N Engl J Med
. 2006 Jun;
354(25):2655-66.
PMID: 16790698
Background: We conducted a double-blind, randomized, placebo-controlled trial to determine the effects of oral cyclophosphamide on lung function and health-related symptoms in patients with evidence of active alveolitis and scleroderma-related...
8.
Shakarjian M, Bhatt P, Gordon M, Chang Y, Casbohm S, Rudge T, et al.
J Appl Toxicol
. 2006 Feb;
26(3):239-46.
PMID: 16489579
Matrix metalloproteinases (MMPs), a class of enzymes responsible for the degradation of extracellular matrix proteins, play important roles in inflammatory and immune responses. In skin, MMP-2 (gelatinase A) and MMP-9...
9.
Joglekar A, Tsai F, McCloskey D, Wilson J, Seibold J, Riley D
J Rheumatol
. 2006 Jan;
33(1):61-8.
PMID: 16395751
Objective: . To assess the efficacy and tolerability of bosentan in pulmonary arterial hypertension secondary to systemic sclerosis (SSc-PAH) including patients with restrictive lung disease. Methods: We retrospectively reviewed 23...
10.
Simon P, Pachence J, Belinka B, Poiani G, Lu S, Tozzi C, et al.
Pulm Pharmacol Ther
. 2005 Sep;
19(4):242-50.
PMID: 16150622
A polymeric prodrug of the proline analogue cis-4-hydroxy-l-proline (CHOP), poly(ethylene glycol)-lysine-CHOP or CHOP-PEG, prevents hypoxic pulmonary hypertension in rats by inhibiting collagen accumulation. A more potent prodrug was synthesized by...